Newly Listed Guardian Pharmacy Is Well Positioned In Highly Fragmented Market, Analyst Initiates With Buy Rating
Newly Listed Guardian Pharmacy Is Well Positioned In Highly Fragmented Market, Analyst Initiates With Buy Rating
Truist notes the sizable market opportunity of around $24.8 billion of U.S. institutional pharmacy revenue in 2024.Truist Securities has initiated coverage on Guardian Pharmacy Services, Inc (NYSE:GRDN), which operates long-term care pharmacies that facilitate the full lifecycle of pharmacy administration and associated consultative services for residents of long-term healthcare facilities (LTCFs).
Truist Securities已開始對長期護理藥房服務公司Guardian Pharmacy Services, Inc (NYSE:GRDN) 進行覆蓋，該公司經營長期護理藥房，提供長期醫療保健設施（LTCFs）居民的全面藥房管理和相關諮詢服務。
As of June 30, 2024, the company operated 50 pharmacies that served approximately 174,000 residents in approximately 6,700 LTCFs across 36 states.
截至2024年6月30日，該公司運營着50家藥房，爲36個州的大約6,700個LTCFs的約174,000名居民提供服務。
Guardian Pharmacy Services priced its initial public offering of 8 million shares at $14.00 per share. The company started trading on September 26.
Guardian Pharmacy Services以每股14.00美元的價格定價其800萬股的首次公開發行。該公司於9月26日開始交易。
Truist notes the sizable market opportunity of around $24.8 billion of U.S. institutional pharmacy revenue in 2024.
Truist指出，2024年美國機構藥房收入約爲248億美元的巨大市場機會。
The analyst observes strong industry trends driven by the aging U.S. population and an increase in residents at assisted living facilities, along with a rise in chronic conditions and multiple diagnoses.
分析師觀察到由美國人口老齡化、輔助生活設施居民增加、慢性疾病和多診斷增加等驅動的強勁行業趨勢。
"Given these industry dynamics, we view Guardian as well positioned given their differentiated scale, suite of capabilities," Truist analyst writes.
"鑑於這些行業動態，我們認爲Guardian在很好的定位，由於其與衆不同的規模和一系列能力，" Truist分析師寫道。
The analyst sees a market share of over 12%, with a leading presence in many regions and an impressive assisted living resident adoption rate of approximately 88%.
分析師認爲其市場份額超過12％，在許多地區具有領先地位，並且在輔助生活居民採用率上達到約88％的印象深刻。
The analyst adds that Guardian has strategically targeted the more lucrative markets of assisted living and behavioral health facilities/group homes.
分析師補充說，Guardian已經戰略地瞄準了更有利可圖的輔助生活和行爲健康機構/集體住所市場。
The analyst initiates with a Buy rating and a price target of $22.
該分析師首次給予買入評級，並設定22美元的目標價格。
Truist says the industry dynamics are advantageous, as the market is notably fragmented, and regulatory requirements create significant barriers to entry. Additionally, demographic trends are likely to provide a boost, particularly as the aging population increasingly relies on prescription medications.
Truist表示，行業動態有利，市場明顯分散，監管要求造成了重要的准入壁壘。此外，人口結構趨勢可能會提供提振，尤其是隨着老齡化人口越來越依賴處方藥。
Stable margins have accompanied Guardian's rapid membership growth, and the company's strong cash flow and appealing financial flexibility will enable continued investments in growth and M&A, the analyst says.
分析師表示，穩定的利潤率伴隨着Guardian快速增長的會員數量，公司強勁的現金流和吸引人的財務靈活性將使其能夠繼續投資於增長和併購。
Lastly, Truist foresees ongoing expansion efforts in new and established markets via organically and M&A activities.
最後，Truist預計通過有機擴張和併購活動在新興和成熟市場進行持續擴張。
Price Action: GRDN stock is down 1.13% at $17.48 at last check Monday.
股價走勢：GRDN股票在上週一最後查看時下跌了1.13%，報17.48美元。
Image: Akava Photo from Pixabay
圖片來自Pixabay的Akava照片。
- Eli Lilly Sues Some Vendors For Unauthorized Sale Of Fake Weight-Loss Drug.
- Eli Lilly起訴一些供應商未經授權銷售假減肥藥。
譯文內容由第三人軟體翻譯。
